CAJ | 학술논문

目的观察亚甲基四氢叶酸还原酶(MTHFR) C667T基因多态性与5-氟尿嘧啶(5-Fu)为基础的化疗方案治疗晚期胃癌的疗效.方法收集经病理学确诊的晚期胃癌59例.所有病例化疗前抽取外周静脉血,提取DNA,用连接酶检测反应技术(LDR)检测研究对象的MTHFR基因型.患者均采用经5-Fu为基础的联合化疗方案.结果 59例晚期胃癌患者MTHFR T/T基因型患者的无进展生存期(PFS)明显优于C/C型(8.70个月比5.47个月x=9.209,P＜0.01),MTHFR T/T基因型患者的PFS明显优于C/T型(8.70个月比5.08个月,x=9.405,P＜0.01),MTHFR C/T基因型患者的PFS与C/C型比较差异无统计学意义(5.47个月比5.08个月,x=0.092,P＞0.05).结论 MTHFR基因型对预测以5-Fu为基础化疗方案治疗晚期胃癌的疗效有较好的临床意义.
목적 관찰아갑기사경협산환원매(MTHFR) C667T기인다태성여5-불뇨밀정(5-Fu)위기출적화료방안치료만기위암적료효.방법 수집경병이학학진적만기위암59례.소유병례화료전추취외주정맥혈,제취DNA,용련접매검측반응기술(LDR)검측연구대상적MTHFR기인형.환자균채용경5-Fu위기출적연합화료방안.결과 59례만기위암환자MTHFR T/T기인형환자적무진전생존기(PFS)명현우우C/C형(8.70개월비5.47개월x=9.209,P＜0.01),MTHFR T/T기인형환자적PFS명현우우C/T형(8.70개월비5.08개월,x=9.405,P＜0.01),MTHFR C/T기인형환자적PFS여C/C형비교차이무통계학의의(5.47개월비5.08개월,x=0.092,P＞0.05).결론 MTHFR기인형대예측이5-Fu위기출화료방안치료만기위암적료효유교호적림상의의.
Objective To study the methylene tetrahydrofolate reductase (MTHFR) C667T gene polymorphism and the therapeutic effect of 5-fluorouracil (5-Fu)-based chemotherapy for adanced gastric cancer patients.Methods Fifty-nine cases of pathologically diagnosed adanced gastric cancer were collected.Peripheral venous blood of all patients was drawn before chemotherapy,and DNA was extracted,and then the MTHFR genotype was detected with ligase detection reaction (LDR).All patients were treated with 5-Fu-based combined chemotherapy.Results Progression-free survival (PFS) of adanced gastric cancer patients with MTHFR T/T genotype was significantly longer than that of patients with MTHFR C/C genotype (8.70 months vs.5.47 months,x2 =9.209,P ＜ 0.01),and that of patients with MTHFR T/T genotype was significantly longer than that of patients with MTHFR C/T genotype (8.70 months vs.5.08months,x2 =9.405,P ＜0.01).There was no significant difference in PFS between patients with MTHFR C/T genotype and those with MTHFR C/C genotype (5.47 months vs.5.08 months,x2 =O.092,P ＞0.05).Conclusion MTHFR genotype has good clinical significance for predicting the therapeutic effect of 5-Fu-based chemotherapy for adanced gastric cancer.